These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37775682)

  • 81. Observational 6-month open-label study of Japanese type 2 diabetes patients switching from NPH insulin to insulin detemir in basal-bolus regimen: 23rd article of the Japan Diabetes Clinical Data Management Study Group (JDDM23).
    Oishi M; Abe N; Yokoyama H; Kuribayashi N; Tomonaga O; Matoba K; Kobayashi M;
    J Int Med Res; 2012; 40(2):787-97. PubMed ID: 22613444
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?
    Valensi P; Cosson E
    Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S34-4S39. PubMed ID: 16389896
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The use of insulin detemir during pregnancy: a safety evaluation.
    Koren R; Toledano Y; Hod M
    Expert Opin Drug Saf; 2015 Apr; 14(4):593-9. PubMed ID: 25731934
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Insulin Detemir Versus Glibenclamide in Gestational Diabetes Mellitus: A Retrospective Cohort Study.
    Ravid D; Kovo M; Leytes S; Yagur Y; Fakterman M; Weitzner O
    Isr Med Assoc J; 2023 Jun; 25(6):398-401. PubMed ID: 37381932
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM; Perry CM
    Drugs; 2004; 64(22):2577-95. PubMed ID: 15516157
    [TBL] [Abstract][Full Text] [Related]  

  • 86. [POET2 registry: Comparison of annual direct medical costs of treating type 2 diabetes after addition of insulin NPH or insulin glargine to oral antidiabetic therapy in the Czech Republic].
    Kvapil M; Žďarská DJ; Suchopár J; Prokeš M; Brož J
    Vnitr Lek; 2015 Jan; 61(1):24-32. PubMed ID: 25693613
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
    Dornhorst A; Lüddeke HJ; Koenen C; Meriläinen M; King A; Robinson A; Sreenan S;
    Diabetes Obes Metab; 2008 Jan; 10(1):75-81. PubMed ID: 18034846
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Twice- rather than once-daily basal insulin is associated with better glycaemic control in Type 1 diabetes mellitus 12 months after skills-based structured education in insulin self-management.
    Hopkinson HE; Jacques RM; Gardner KJ; Amiel SA; Mansell P
    Diabet Med; 2015 Aug; 32(8):1071-6. PubMed ID: 25982032
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Metformin compared with insulin in the management of gestational diabetes mellitus: a randomized clinical trial.
    Niromanesh S; Alavi A; Sharbaf FR; Amjadi N; Moosavi S; Akbari S
    Diabetes Res Clin Pract; 2012 Dec; 98(3):422-9. PubMed ID: 23068960
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
    Fritsche A; Schweitzer MA; Häring HU;
    Ann Intern Med; 2003 Jun; 138(12):952-9. PubMed ID: 12809451
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Safety and effectiveness of insulin detemir in combination with oral antidiabetic agents in an outpatient specialist setting: results of the Italian SOLVE™ observational study.
    Caputo S; Maran A; Mannino D; Morano S; Lastoria G; Nicoziani P
    Minerva Endocrinol; 2015 Dec; 40(4):249-58. PubMed ID: 26551483
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Improved glycemic control and lower frequency of severe hypoglycemia with insulin detemir; long-term experience in 105 children and adolescents with type 1 diabetes.
    Braun D; Konrad D; Lang-Muritano M; Schoenle E
    Pediatr Diabetes; 2008 Aug; 9(4 Pt 2):382-7. PubMed ID: 18331413
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis.
    Pscherer S; Chou E; Dippel FW; Rathmann W; Kostev K
    Prim Care Diabetes; 2015 Oct; 9(5):377-84. PubMed ID: 25701545
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.
    Rosenstock J; Fonseca V; Schinzel S; Dain MP; Mullins P; Riddle M
    J Diabetes Complications; 2014; 28(5):742-9. PubMed ID: 24856612
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults.
    Strandberg AY; Khanfir H; Mäkimattila S; Saukkonen T; Strandberg TE; Hoti F
    Ann Med; 2017 Jun; 49(4):357-364. PubMed ID: 28042719
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Defining the role of insulin detemir in Basal insulin therapy.
    Morales J
    Drugs; 2007; 67(17):2557-84. PubMed ID: 18034591
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trial.
    Mathiesen ER; Alibegovic AC; Corcoy R; Dunne F; Feig DS; Hod M; Jia T; Kalyanam B; Kar S; Kautzky-Willer A; Marchesini C; Rea RD; Damm P;
    Lancet Diabetes Endocrinol; 2023 Feb; 11(2):86-95. PubMed ID: 36623517
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study.
    Gordon J; Pockett RD; Tetlow AP; McEwan P; Home PD
    Int J Clin Pract; 2010 Nov; 64(12):1609-18. PubMed ID: 20946269
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A bridge to insulin pump therapy: twice-daily regimen with NPH and detemir insulins during initial treatment of youth with type 1 diabetes mellitus.
    Cengiz E; Sherr JL; Erkin-Cakmak A; Weinzimer SA; Burke EN; Sikes KA; Urban AD; Tamborlane WV
    Endocr Pract; 2011; 17(6):862-6. PubMed ID: 21550949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.